Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Frazer

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Medicine, Science, and the Law|December 29, 2006
Arson: a growing infernoAnand Jayaraman, John Frazer
Current Opinion in Biotechnology|November 1, 2005
Functional assays for screening GPCR targetsWilliam Thomsen, John Frazer, David Unett
Cellular Signalling|June 22, 2018
Angiotensin (1-7) does not interact directly with MAS1, but can potently antagonize signaling from the AT1 receptorIbragim Gaidarov, John Adams, John Frazer, et al.
Cellular Signalling|April 1, 2025
Mechanisms of constitutive and agonist-induced 5-HT<sub>2B</sub> internalization, persistent endosomal signaling and paradoxical regulation of agonist pharmacologyIbragim Gaidarov, John Frazer, Xiaohua Chen, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 25, 2009
APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biologyJohn W Adams, Juan Ramirez, Yunqing Shi, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 20, 2013
Kinetics of 5-HT2B receptor signaling: profound agonist-dependent effects on signaling onset and durationDavid J Unett, Joel Gatlin, Todd L Anthony, et al.
Bioorganic & Medicinal Chemistry Letters|January 19, 2020
Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assaysAlbert Ren, Xiuwen Zhu, Konrad Feichtinger, et al.
Journal of Medicinal Chemistry|May 14, 2025
Diazepine Agonists of the 5-HT<sub>2C</sub> Receptor with Unprecedented Selectivity: Discovery of Bexicaserin (LP352)Albert Ren, Xiuwen Zhu, Juerg Lehmann, et al.
Bioorganic & Medicinal Chemistry Letters|February 26, 2021
Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT<sub>2C</sub> receptorThomas O Schrader, Xiuwen Zhu, Michelle Kasem, et al.
Bioorganic & Medicinal Chemistry Letters|June 17, 2008
Novel H3 receptor antagonists with improved pharmacokinetic profilesVincent J Santora, Jonathan A Covel, Rena Hayashi, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Medicine, Science, and the Law|December 29, 2006
Arson: a growing infernoAnand Jayaraman, John Frazer
Current Opinion in Biotechnology|November 1, 2005
Functional assays for screening GPCR targetsWilliam Thomsen, John Frazer, David Unett
Cellular Signalling|June 22, 2018
Angiotensin (1-7) does not interact directly with MAS1, but can potently antagonize signaling from the AT1 receptorIbragim Gaidarov, John Adams, John Frazer, et al.
Cellular Signalling|April 1, 2025
Mechanisms of constitutive and agonist-induced 5-HT<sub>2B</sub> internalization, persistent endosomal signaling and paradoxical regulation of agonist pharmacologyIbragim Gaidarov, John Frazer, Xiaohua Chen, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 25, 2009
APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biologyJohn W Adams, Juan Ramirez, Yunqing Shi, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 20, 2013
Kinetics of 5-HT2B receptor signaling: profound agonist-dependent effects on signaling onset and durationDavid J Unett, Joel Gatlin, Todd L Anthony, et al.
Bioorganic & Medicinal Chemistry Letters|January 19, 2020
Discovery of a lead series of potent benzodiazepine 5-HT<sub>2C</sub> receptor agonists with high selectivity in functional and binding assaysAlbert Ren, Xiuwen Zhu, Konrad Feichtinger, et al.
Journal of Medicinal Chemistry|May 14, 2025
Diazepine Agonists of the 5-HT<sub>2C</sub> Receptor with Unprecedented Selectivity: Discovery of Bexicaserin (LP352)Albert Ren, Xiuwen Zhu, Juerg Lehmann, et al.
Bioorganic & Medicinal Chemistry Letters|February 26, 2021
Novel (R)-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines as potent and selective agonists of the 5-HT<sub>2C</sub> receptorThomas O Schrader, Xiuwen Zhu, Michelle Kasem, et al.
Bioorganic & Medicinal Chemistry Letters|June 17, 2008
Novel H3 receptor antagonists with improved pharmacokinetic profilesVincent J Santora, Jonathan A Covel, Rena Hayashi, et al.
Pageof 2